[go: up one dir, main page]

MX2017002489A - Agentes terapeuticos humanos. - Google Patents

Agentes terapeuticos humanos.

Info

Publication number
MX2017002489A
MX2017002489A MX2017002489A MX2017002489A MX2017002489A MX 2017002489 A MX2017002489 A MX 2017002489A MX 2017002489 A MX2017002489 A MX 2017002489A MX 2017002489 A MX2017002489 A MX 2017002489A MX 2017002489 A MX2017002489 A MX 2017002489A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
human therapeutic
human
component
agents
Prior art date
Application number
MX2017002489A
Other languages
English (en)
Inventor
H Zaid Gene
w burgoyne Thomas
Original Assignee
Ions Pharmaceutical S À R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/721,011 external-priority patent/US9402834B2/en
Application filed by Ions Pharmaceutical S À R L filed Critical Ions Pharmaceutical S À R L
Publication of MX2017002489A publication Critical patent/MX2017002489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con composiciones de tratamiento terapéuticas humanas que comprenden por lo menos dos de un componente de curcumina, un componente de harmina y un componente de isovainillina, y de preferencia, los tres en combinación. Los agentes son efectivos para el tratamiento de afecciones humanas, especialmente cánceres humanos.
MX2017002489A 2014-10-21 2015-10-16 Agentes terapeuticos humanos. MX2017002489A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462066686P 2014-10-21 2014-10-21
US201562161090P 2015-05-13 2015-05-13
US14/721,011 US9402834B2 (en) 2014-10-21 2015-05-26 Human therapeutic agents
US201562184051P 2015-06-24 2015-06-24
PCT/US2015/055968 WO2016064676A1 (en) 2014-10-21 2015-10-16 Human therapeutic agents

Publications (1)

Publication Number Publication Date
MX2017002489A true MX2017002489A (es) 2017-09-13

Family

ID=55761352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002489A MX2017002489A (es) 2014-10-21 2015-10-16 Agentes terapeuticos humanos.

Country Status (13)

Country Link
EP (2) EP3188721B1 (es)
JP (1) JP6937237B2 (es)
KR (1) KR20170066425A (es)
CN (3) CN115569136A (es)
AU (1) AU2015336311B2 (es)
CA (1) CA2955114C (es)
DK (1) DK3188721T3 (es)
ES (1) ES2744913T3 (es)
IL (1) IL250990A0 (es)
MX (1) MX2017002489A (es)
RU (1) RU2017115885A (es)
TW (1) TW201625230A (es)
WO (1) WO2016064676A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016181220A2 (en) * 2015-05-13 2016-11-17 Ions Pharmaceutical S.À R.L. Therapeutic compositions and methods of use thereof
CA3086925A1 (en) 2018-01-05 2019-07-11 Ichan School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
US11246902B2 (en) * 2018-02-23 2022-02-15 Ankh Life Sciences Limited Nutritional supplement for mammals
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US11452715B2 (en) 2018-04-13 2022-09-27 Ankh Life Sciences Limited Thymoquinone/harmaline and related reaction products
US11453664B2 (en) 2018-04-13 2022-09-27 Ankh Life Sciences Limited Thymoquinone/harmaline and related reaction products
US11453665B2 (en) 2018-04-13 2022-09-27 Ankh Life Sciences Limited Thymoquinone/harmaline and related reaction products
US10875859B2 (en) 2018-04-13 2020-12-29 Ankh Life Sciences Limited Thymoquinone/harmaline and related reaction products
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
US12419872B2 (en) 2020-03-05 2025-09-23 Ankh Life Sciences Limited Low-temperature synthesis of thymoquinone and harmaline compounds
WO2022019892A1 (en) * 2020-07-21 2022-01-27 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
JP2023080697A (ja) * 2021-11-30 2023-06-09 株式会社渡辺オイスター研究所 転移性ヒト前立腺がん細胞の増殖抑制剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
JP2004075666A (ja) * 2002-05-15 2004-03-11 Keio Gijuku 造血器腫瘍の治療薬、免疫抑制剤、およびｐ５３を標的分子とする分子標的治療薬
CN100503607C (zh) * 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
FR2869540B1 (fr) * 2004-04-30 2008-05-16 Centre Nat Rech Scient Cnrse Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
CN100553628C (zh) * 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
CN101669931B (zh) * 2008-09-08 2012-07-04 北京鼎国昌盛生物技术有限责任公司 长效姜黄素衍生物在制备抗肿瘤症药物中的应用
EP2418943A4 (en) * 2009-04-15 2012-08-29 Univ Ohio State Res Found CURCUMIN ANALOGUES AS DOUBLE JAK2 / STAT3 INHIBITORS AND METHODS FOR THE PREPARATION AND USE THEREOF
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US20120058208A1 (en) * 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
WO2012047852A2 (en) * 2010-10-07 2012-04-12 The J. David Gladstone Institutes Compositions and methods for modulating immunodeficiency virus transcription
US8039025B1 (en) 2010-10-15 2011-10-18 Life Plus, LLC Methods and dosage forms for the treatment of human cancers
WO2015006646A1 (en) * 2013-07-11 2015-01-15 Specialty Nutrition Group, Inc. Compositions comprising hydroxytyrosol, curcumin, and/or astaxanthin and use thereof

Also Published As

Publication number Publication date
CN107106519A (zh) 2017-08-29
IL250990A0 (en) 2017-04-30
TW201625230A (zh) 2016-07-16
CA2955114C (en) 2023-01-03
AU2015336311A1 (en) 2017-02-09
CN107106519B (zh) 2023-01-24
WO2016064676A1 (en) 2016-04-28
ES2744913T3 (es) 2020-02-26
JP2017531689A (ja) 2017-10-26
DK3188721T3 (da) 2019-08-12
CN115569136A (zh) 2023-01-06
AU2015336311B2 (en) 2020-05-14
CN110772512A (zh) 2020-02-11
AU2015336311A2 (en) 2020-02-06
EP3188721A1 (en) 2017-07-12
JP6937237B2 (ja) 2021-09-22
EP3188721B1 (en) 2019-06-12
KR20170066425A (ko) 2017-06-14
BR112017006190A2 (pt) 2017-12-26
RU2017115885A (ru) 2018-11-23
EP3275465A1 (en) 2018-01-31
EP3188721A4 (en) 2018-05-02
EP3275465B1 (en) 2020-05-06
CA2955114A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
IL291922B1 (en) FAP-activated medical materials and related uses
MX2017002489A (es) Agentes terapeuticos humanos.
ZA202004557B (en) Modulatory polynucleotides
MY187540A (en) Compounds active towards bromodomains
GB2541571A (en) Pharmaceutical compositions
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3250589A4 (en) Therapeutic and diagnostic agents
EP3148526A4 (en) Use of eribulin in the treatment of cancer
IL273470A (en) Semaglutide in medical treatment
TW201713323A (en) Therapeutic compositions and methods of use thereof
PH12017500602A1 (en) Methods for treating ocular conditions
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
PH12016501838A1 (en) Compounds and their methods of use
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3222281A4 (en) Preventive and therapeutic agent for celiac disease
IL274866A (en) Preparations and methods for the treatment of cancer
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
HK40026666A (en) Semaglutide in medical therapy
HK1237265A1 (en) Combination therapy compositions and methods for treating cancers
GB2553684B (en) Ethynylxanthines, preparation and use for cancer treatment
HK40002219A (en) Cancer treatment combination compositions, methods and uses
AU2017902160A0 (en) New Therapeutic Treatment Combination
HK1242990A1 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer